Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Outstanding
Ratios

Cytokinetics (CYTK) Accumulated Depreciation & Amortization: 2009-2024

Historic Accumulated Depreciation & Amortization for Cytokinetics (CYTK) over the last 2 years, with Dec 2024 value amounting to $37.2 million.

  • Cytokinetics' Accumulated Depreciation & Amortization rose 31.15% to $37.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was $98.8 million, marking a year-over-year increase of 14.53%. This contributed to the annual value of $37.2 million for FY2024, which is 31.15% up from last year.
  • Cytokinetics' Accumulated Depreciation & Amortization amounted to $37.2 million in Q4 2024, which was up 31.15% from $28.3 million recorded in Q4 2023.
  • Cytokinetics' Accumulated Depreciation & Amortization's 5-year high stood at $37.2 million during Q4 2024, with a 5-year trough of $16.2 million in Q4 2021.
  • In the last 3 years, Cytokinetics' Accumulated Depreciation & Amortization had a median value of $28.3 million in 2023 and averaged $27.5 million.
  • Per our database at Business Quant, Cytokinetics' Accumulated Depreciation & Amortization plummeted by 34.30% in 2021 and then soared by 65.84% in 2023.
  • Cytokinetics' Accumulated Depreciation & Amortization (Quarterly) stood at $24.6 million in 2020, then slumped by 34.30% to $16.2 million in 2021, then increased by 5.59% to $17.1 million in 2022, then surged by 65.84% to $28.3 million in 2023, then surged by 31.15% to $37.2 million in 2024.
  • Its last three reported values are $37.2 million in Q4 2024, $28.3 million for Q4 2023, and $17.1 million during Q4 2022.